IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans

American Journal of Physiology - Endocrinology and Metabolism

Volumn 285, Issue 2 48-2, 2003, Pages

  Steensberg, Adam ^a,b,c   Fischer, Christian P ^a,b   Keller, Charlotte ^a,b   Møller, Kirsten ^b   Pedersen, Bente Klarlund ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

C reactive protein; Cytokines; Interleukin 1 receptor agonist; Neutrophils and lymphocytes; Tumor necrosis factor

Indexed keywords

ADRENALIN; HYDROCORTISONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADRENALIN BLOOD LEVEL; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DOSE RESPONSE; EXERCISE; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMMUNE RESPONSE; INFLAMMATION; LYMPHOCYTE; MALE; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0041846867     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00074.2003     Document Type: Article

References (36)

1. Abernathy VJ, Webster RO, and Dahms TE. C-reactive protein inhibits increased pulmonary vascular permeability induced by fMLP in isolated rabbit lungs. Am J Physiol Heart Circ Physiol 271: H507-H513, 1996.
2. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, and Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85: 3338-3342, 2000.
3. Bethin KE, Vogt SK, and Muglia LJ. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA 97: 9317-9322, 2000.
4. Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, and Pedersen BK. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 54: M357-M364, 1999.
5. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, and Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 89: 9991-9995, 1992.
6. Dickensheets HL, Freeman SL, Smith MF, and Donnelly RP. Interleukin-10 upregulates tumor necrosis factor receptor type-II (p75) gene expression in endotoxin-stimulated human monocytes. Blood 90: 4162-4171, 1997.
7. Dinarello CA. Induction of interleukin-1 and interleukin-1 receptor antagonist. Semin Oncol 24: S9, 1997.
8. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16: 457-499, 1998.
9. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 285: 199-212, 1991.
10. Foldes-Filep E, Filep JG, and Sirois P. C-reactive protein inhibits intracellular calcium mobilization and superoxide production by guinea pig alveolar macrophages. J Leukoc Biol 51: 13-18, 1992.
11. Heuertz RM, Piquette CA, and Webster RO. Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis. Am J Pathol 142: 319-328, 1993.
12. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, and Brennan FM. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 24: 2699-2705, 1994.
13. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, and Yano Y. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83: 859-862, 1998.
14. Keller C, Steensberg A, Pilegaard H, Osada T, Saltin B, Pedersen BK, and Neufer PD. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15: 2748-2750, 2001.
15. Lyngso D, Simonsen L, and Bulow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 543: 379-386, 2002.
16. Matthys P, Mitera T, Heremans H, Van Damme J, and Billiau A. Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice. Infect Immun 63: 1158-1164, 1995.
17. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, and Kibata M. Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with type 2 diabetes mellitus. Diabetes Res Clin Pract 52: 119-123, 2001.
18. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H, and Fujiwara H. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 179: 1529-1537, 1994.
19. Opal SM and DePalo VA. Anti-inflammatory cytokines. Chest 117: 1162-1172, 2000.
20. Ostrowski K, Hermann C, Bangash A, Schjerling P, Nielsen JN, and Pedersen BK. A trauma-like elevation of plasma cytokines in humans in response to treadmill running. J Physiol 513: 889-894, 1998.
21. Ostrowski K, Rohde T, Asp S, Schjerling P, and Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol 515: 287-291, 1999.
22. Pedersen BK and Hoffman-Goetz L. Exercise and the immune system: regulation, integration, and adaptation. Physiol Rev 80: 1055-1081, 2000.
23. Pedersen BK, Steensberg A, and Schjerling P. Muscle-derived interleukin-6: possible biological effects. J Physiol 536: 329-337, 2001.
24. Pickup JC, Chusney GD, Thomas SM, and Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67: 291-300, 2000.
25. Ridker PM, Rifai N, Stampfer MJ, and Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 17, 2000.
26. a. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, and Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-α production in humans. FASEB J 17: 884-886, 2003.
27. Steensberg A, Febbraio MA, Osada T, Schjerling P, van Hall G, Saltin B, and Pedersen BK. Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 537: 633-639, 2001.
28. Steensberg A, Morrow J, Toft D, Bruunsgaard H, and Pedersen BK. Prolonged exercise, lymphocyte apoptosis and F2-isoprostanes. Eur J Appl Physiol 87: 38-42, 2002.
29. Steensberg A, Toft AD, Bruunsgaard H, Sandmand M, Halkjaer-Kristensen J, and Pedersen BK. Strenuous exercise decreases the percentage of type 1 T cells in the circulation. J Appl Physiol 91: 1708-1712, 2001.
30. Steensberg A, Toft AD, Schjerling P, Halkjaer-Kristensen J, and Pedersen BK. Plasma interleukin-6 during strenuous exercise: role of epinephrine. Am J Physiol Cell Physiol 281: C1001-C1004, 2001.
31. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, and Pedersen BK. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529: 237-242, 2000.
32. Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, and Sauerwein HP. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab 268: E813-E819, 1995.
33. Tilg H, Dinarello CA, and Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 18: 428-432, 1997.
34. Tilg H, Trehu E, Atkins MB, Dinarello CA, and Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83: 113-118, 1994.
35. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, and Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9: 414-417, 2001.
36. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, and Achong MK. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101: 311-320, 1998.